Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0588 CHF | +6.91% | +13.95% | +43.41% |
Apr. 17 | Santhera Pharmaceuticals Terminates Cystic Fibrosis Drug License Deal with Spexis | MT |
Apr. 17 | Swiss Court OKs Moratorium Extension for Spexis | MT |
Sales 2021 | 331 362.66 | Sales 2022 | 1.48M 1.62M | Capitalization | 19.96M 21.87M |
---|---|---|---|---|---|
Net income 2021 | -11M -12.05M | Net income 2022 | -18M -19.72M | EV / Sales 2021 * | - |
Net cash position 2021 | 6.23M 6.83M | Net Debt 2022 | 4.23M 4.64M | EV / Sales 2022 | 16.4 x |
P/E ratio 2021 * |
-
| P/E ratio 2022 |
-1.07
x | Employees | 28 |
Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 46.61% |
Latest transcript on Spexis AG
1 day | +6.91% | ||
1 week | +13.95% | ||
Current month | -30.82% | ||
1 month | -23.64% | ||
3 months | -84.92% | ||
6 months | -72.00% | ||
Current year | +43.41% |
Managers | Title | Age | Since |
---|---|---|---|
Jeffrey Wager
CEO | Chief Executive Officer | 62 | 21-12-29 |
Martin Jakobovic
DFI | Director of Finance/CFO | - | - |
Stephan Wehselau
COO | Chief Operating Officer | 55 | 21-12-29 |
Members of the board | Title | Age | Since |
---|---|---|---|
Dan Hartman
BRD | Director/Board Member | 62 | 21-12-29 |
Dennis Ausiello
BRD | Director/Board Member | 78 | 21-12-29 |
Kuno Sommer
BRD | Director/Board Member | 68 | 12-08-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-25 | 0.0588 | +6.91% | 15,392 |
24-04-24 | 0.055 | -6.78% | 70,500 |
24-04-23 | 0.059 | +2.43% | 166,217 |
24-04-22 | 0.0576 | +4.73% | 158,616 |
24-04-19 | 0.055 | +6.59% | 37,501 |
Delayed Quote Swiss Exchange, April 25, 2024 at 11:31 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
+43.41% | 4.07M | |
-2.86% | 87.31B | |
+2.63% | 40.86B | |
-21.76% | 29.36B | |
+58.56% | 24.49B | |
-14.78% | 17.31B | |
-18.49% | 11.62B | |
-15.61% | 11.31B | |
-44.02% | 11.26B | |
+5.17% | 8.31B |
- Stock Market
- Equities
- POLN Stock